Angela Karani
Overview
Explore the profile of Angela Karani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coldiron M, Soumana I, Baudin E, Langendorf C, Mamiafo Tchoula C, Brah S, et al.
Lancet Infect Dis
. 2025 Jan;
PMID: 39798587
Background: In settings with low pneumococcal conjugate vaccine (PCV) coverage, multi-age cohort mass campaigns could increase population immunity, and fractional dosing could increase affordability. We aimed to evaluate the effect...
2.
Lugano D, Kutima B, Kimani M, Sigilai A, Gitonga J, Karani A, et al.
BMC Infect Dis
. 2024 Dec;
24(1):1474.
PMID: 39732637
Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing...
3.
Gallagher K, Lucinde R, Bottomley C, Kaniu M, Suaad B, Mutahi M, et al.
N Engl J Med
. 2024 Sep;
391(21):2003-2013.
PMID: 39330966
Background: Pneumococcal conjugate vaccines are an expensive component of the routine immunization schedule. Fractional-dose regimens may be one option to increase the sustainability of the vaccine program. Methods: We assessed...
4.
Muthumbi E, Mwanzu A, Mbae C, Bigogo G, Karani A, Mwarumba S, et al.
PLoS Negl Trop Dis
. 2023 Oct;
17(10):e0011716.
PMID: 37883602
Background: Despite the importance of non-Typhoidal Salmonella (NTS) disease in Africa, epidemiologic data on carriage and transmission are few. These data are important to understand the transmission of NTS in...
5.
Gallagher K, Nyiro J, Agoti C, Maitha E, Nyagwange J, Karani A, et al.
Influenza Other Respir Viruses
. 2023 Sep;
17(9):e13185.
PMID: 37752066
Background: We estimated the secondary attack rate of SARS-CoV-2 among household contacts of PCR-confirmed cases of COVID-19 in rural Kenya and analysed risk factors for transmission. Methods: We enrolled incident...
6.
Kagucia E, Ziraba A, Nyagwange J, Kutima B, Kimani M, Akech D, et al.
Influenza Other Respir Viruses
. 2023 Sep;
17(9):e13173.
PMID: 37752065
Background: We sought to estimate SARS-CoV-2 antibody seroprevalence within representative samples of the Kenyan population during the third year of the COVID-19 pandemic and the second year of COVID-19 vaccine...
7.
Butler M, Jansen van Rensburg M, Karani A, Mvera B, Akech D, Akter A, et al.
Microb Genom
. 2023 Jul;
9(7).
PMID: 37436819
No abstract available.
8.
Gallagher K, Adetifa I, Mburu C, Bottomley C, Akech D, Karani A, et al.
Lancet Infect Dis
. 2023 Jul;
23(11):1291-1301.
PMID: 37429307
Background: In Kilifi (Kenya), a pneumococcal conjugate vaccine (PCV10) was introduced in 2011 in infants (aged <1 year, 3 + 0 schedule) with a catch-up campaign in children aged 1-4...
9.
Adamu A, Ojal J, Abubakar I, Odeyemi K, Bello M, Okoromah C, et al.
Nat Commun
. 2023 May;
14(1):2666.
PMID: 37160867
Pneumococcal conjugate vaccines (PCVs) protect against invasive pneumococcal disease (IPD) among vaccinees. However, at population level, this protection is driven by indirect effects. PCVs prevent nasopharyngeal acquisition of vaccine-serotype (VT)...
10.
Etyang A, Adetifa I, Omore R, Misore T, Ziraba A, Ngoda M, et al.
PLOS Glob Public Health
. 2023 Mar;
2(8):e0000883.
PMID: 36962821
Background: Most of the studies that have informed the public health response to the COVID-19 pandemic in Kenya have relied on samples that are not representative of the general population....